Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 15.38 GBp
Change Today +0.25 / 1.65%
Volume 52.0K
ODX On Other Exchanges
Symbol
Exchange
London
As of 11:30 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

omega diagnostics group plc (ODX) Snapshot

Open
15.13 GBp
Previous Close
15.13 GBp
Day High
15.38 GBp
Day Low
15.13 GBp
52 Week High
06/9/15 - 26.63 GBp
52 Week Low
04/8/15 - 12.63 GBp
Market Cap
16.7M
Average Volume 10 Days
102.5K
EPS TTM
0.0071 GBp
Shares Outstanding
108.7M
EX-Date
--
P/E TM
21.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for OMEGA DIAGNOSTICS GROUP PLC (ODX)

Related News

No related news articles were found.

omega diagnostics group plc (ODX) Related Businessweek News

No Related Businessweek News Found

omega diagnostics group plc (ODX) Details

Omega Diagnostics Group PLC, together with its subsidiaries, manufactures, develops, and distributes medical diagnostics products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases. The Allergy and Autoimmune segment researches, develops, produces, and markets in vitro allergy and autoimmune tests that are used by doctors to diagnose patients with allergies and autoimmune diseases. This segment’s principal products include Allergozyme, Allergodip, and Genesis Elisa. The Food Intolerance segment engages in the research, development, and production of kits to aid the detection of immune reactions to food. This segment also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies consumer food detective test products. Its principal products include Genarrayt/Foodprint, Food Detective, and CNS laboratory service. The Infectious Diseases segment is involved in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. Its principal products comprise Immutrep Syphilis, Micropath Bacterial tests, and Dengue Elisa. The company offers its products to hospitals, blood banks, clinics, and laboratories through distributors and sales teams in approximately 100 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.

146 Employees
Last Reported Date: 07/8/15
Founded in 1987

omega diagnostics group plc (ODX) Top Compensated Officers

Founder, Chief Executive Officer, Managing Di...
Total Annual Compensation: 145.0K GBP
Group Finance Director, Company Secretary and...
Total Annual Compensation: 115.0K GBP
Group Sales & Marketing Director and Executiv...
Total Annual Compensation: 110.0K GBP
Compensation as of Fiscal Year 2015.

omega diagnostics group plc (ODX) Key Developments

Omega Diagnostics Group PLC Appoints Colin King as Chief Operating Officer, Effective August 3, 2015; Announces Audited Final Consolidated Financial Results for the Year Ended March 31, 2015

Omega Diagnostics Group PLC announced the appointment of Colin King as Chief Operating Officer from 3 August 2015. The company announced audited final consolidated financial results for the year ended March 31, 2015. For the year, the company reported revenue from continuing operations of £12,105,319 against £11,593,870 a year ago. Operating profit was £672,970 against £527,325 a year ago. Profit before taxation was £684,258 against £543,041 a year ago. Profit for the year was £739,046 against £692,851 a year ago. Basic and diluted earnings per share on profit for the year were 0.7 pence against 0.7 pence a year ago. Adjusted profit before taxation for the year ended 31 March 2015 was £1,373,102 against £1,095,911 a year ago. Adjusted earnings per share on profit for the year were 1.3 pence against 1.2 pence a year ago. Cash flow from operating activities was £1,247,893 against £1,669,107 a year ago. Purchase of property, plant and equipment was £701,565 against £478,968 a year ago. Purchase of intangible assets was £1,394,146 against £1,880,845 a year ago.

Omega Diagnostics Group PLC Announces Development Update on its Visitect® CD4 and Allergy

Omega Diagnostics Group PLC announced the development update on its infectious disease and allergy projects. Infectious Disease - Visitect® CD4 update: Since the trading update on 15 April 2015, the Company has continued to test devices on a large number of patient samples with the aim of optimising performance and deciding on suitable in-house manufacturing processes. The Company confirms that it has now made three pilot batches of devices, all of which have yielded comparable results and which demonstrate that Visitect® CD4 is capable of meeting the Company's performance design goals in comparison to flow cytometry when tested on HIV positive patients. The Company confirms that its internal investigation phase is now complete as planned. The outcome of this investigation phase has been the selection of in-house manufacturing processes which are scalable and which will now be subject to verification and validation leading to the release of Visitect® CD4 test devices for re-evaluation in the field. Allergy Development - Allersys® automation update: The allergy development programme has continued to make progress. The company now has 32 allergens that have been optimised to show equivalent performance to the market product. Of these, 22 have completed their claim support work. The manufacturing process and recent amendments to the instrument software have been validated for full scale manufacture and it has now commercial quantities for 27 allergens and associated reagents within the inventory which have all passed internal quality control procedures. These allergens will be used in beta evaluations at sites in Spain and Italy, planned in June and July respectively. A preliminary field study comparing the Allersys® system to ThermoFisher ImmunoCAP® using eight allergens was conducted at Udine University Hospital Laboratory, Italy last year. The investigators concluded that the two systems were comparable. The results of the study have recently been accepted for an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual meeting in Barcelona, 6-10 June 2015.

Omega Diagnostics Group PLC Appoints Colin King as Chief Operating Officer, with Effect from August 3, 2015

Omega Diagnostics Group PLC announced that Colin King has agreed to join the board as Chief Operating Officer and will take up his appointment with effect from August 3, 2015. Mr. King has over 20 years' experience in the in-vitro diagnostics industry and is currently the Managing Director of Axis-Shield Diagnostics, having joined in 1995 and held a number of positions encompassing project management, operations, planning and supply chain logistics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ODX:LN 15.38 GBp +0.25

ODX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ODX.
View Industry Companies
 

Industry Analysis

ODX

Industry Average

Valuation ODX Industry Range
Price/Earnings 23.7x
Price/Sales 1.4x
Price/Book 0.9x
Price/Cash Flow 23.5x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEGA DIAGNOSTICS GROUP PLC, please visit www.omegadiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.